Battelle breakthrough could help autistic children receive treatment sooner

Battelle scientists have identified a low-cost urine test that potentially predicts the presence of autism spectrum disorder (ASD) at an early age.

ASD, which is defined by behavioral characteristics, has been difficult for physicians to diagnose at an early age before these behaviors become more apparent (usually about two years of age or older). Recent research indicates that ASD affects 1 in 88 children in the U.S.

The Battelle team of Drs. Nicholas Heyer and Diana Echeverria joined with Professor James Woods at the University of Washington’s School of Public Health to evaluate the levels of porphyrins in the urine of children with ASD to determine if certain levels of specific porphyrins could predict ASD.

Identifying this link may have important clinical implications for diagnosis and treatment. The ability to detect porphyrins, a group of naturally occurring organic compounds, in a simple urine test allows for a rapid, low-cost and widely used screening test for identifying young children at a high risk for ASD.

“This is significant because it means children may be diagnosed with ASD at an earlier age and can thus receive treatment sooner. Early treatment can lead to a better quality of life for children with ASD,” Heyer said.

The findings were published in this month’s edition of Autism Research, and coincide with Autism Awareness Month.

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

NanoLogix developing rapid test for Ebola virus (video) | WYTV33 Youngstown, October 21, 2014

Analytic, a partnership of Anatrace and Microlytic: enabling membrane protein research | PR Web, October 21, 2014

Quasar Energy Group uses organic waste to produce renewable energy | Todays Energy Solutions, October 21, 2014

Frank Samuel, President of VentureOhio and former BioOhio President dies in auto accident | Geauga County Maple Leaf, October 21, 2014

Milo Biotechnology’s follistatin gene therapy increases function in Becker Muscular Dystrophy patients | PR Newswire, October 20, 2014

OSU Wexner Medical Center study: new implantable device to control heart failure shows promising results | Todays Medical Developments, October 17, 2014

Assurex Health gets $6M funding for clinical trial related to patients with depression or schizophrenia | Cincinnati Business Courier, October 17, 2014

University of Cincinnati lands grant to attack hepatitis C among needle users in 20 counties | WCPO9 Cincinnati, October 16, 2014

Control Bionics interview, developing technology that enables individuals with debilitating conditions to communicate | The Clermont Sun, October 16, 2014

BioOhio member Oralectrics spinout Zumby opens crowdfunding campaign | Cleveland.com, October 16, 2014

Ohio State sophomore Peeyush Shrivastava of Genetesis named a finalist in $5M 43North business plan competition | Columbus Business First, October 16, 2014

Navidea hires Rick Gonzalez as CEO from Spectrum Pharmaceuticals, replaces Michael Goldberg, Navidea’s lead investor | Columbus Business First, October 15, 2014

Health Care DataWorks’ Chief Data Scientist to present at healthcare conference sponsored by HIMSS Georgia Chapter | PR Web, October 15, 2014

FDA approves expanded use of Navidea’s Lymphoseek for lymphatic mapping in solid tumors | Business Wire, October 15, 2014

Crowdfunding launches today for Animal Oralectrics’ new medical device for dogs that fights oral bacteria while playing | PR Newswire, October 15, 2014

NanoLogix technology being configured for rapid Ebola and Enterovirus detection | Business Wire, October 14, 2014

Nanotronics Imaging releases nSPEC 3D, powerful microscope that captures 3D images at nanoscale, in lightning speed | Business Wire, October 14, 2014

Cincinnati Children’s Hospital Medical Center announces a new treatment designed to save more eyes from cancer | PR Newswire, October 14, 2014

Ischemia Care raises $1.9M for stroke detection technology | MedCity News, October 13, 2014

STERIS to acquire Synergy Health for $1.9 Billion in cash and stock | STERIS, October 13, 2014